Skip to main content
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Loss of heterozygosity for chromosome 14q in neuroblastoma.
Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.
Lymphoblast morphology in predicting leukemic meningeal relapse with low chamber count and lymphoblasts.